The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BLTE | +125.81% | N/A | N/A | +1,328% |
| S&P | +12.66% | +85.37% | +13.13% | +66% |
Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
The company is now tantalizingly close to commercializing its leading drug candidate.
The clinical-stage biotech company bounced back from a 52-week low late last week.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.35M | 0.0% |
| Market Cap | $2.41B | 68.1% |
| Market Cap / Employee | $96.49M | 0.0% |
| Employees | 25 | 25.0% |
| Net Income | -$21.69M | -149.9% |
| EBITDA | -$22.67M | -132.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $157.03M | 44.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.25M | 0.0% |
| Short Term Debt | $0.27M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -31.33% | 6.8% |
| Return On Invested Capital | -34.11% | 2.3% |
No data available for this period.
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 17.37 | 14.45 | 11.88 | 16.09 | 28.52% |
| Price to Tangible Book Value | 17.37 | 14.46 | 11.88 | 16.09 | 28.52% |
| Enterprise Value to EBITDA | -160.61 | -126.78 | -98.37 | -96.31 | -29.45% |
| Return on Equity | -30.6% | -33.4% | -37.3% | -32.3% | -19.34% |
| Total Debt | $0.54M | $0.00M | $0.00M | $0.51M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
